FDA’s Decision Boosts Fulcrum Therapeutics; Macy’s Beats Q2 Estimates
- August 22nd, 2023
- 320 views
Shares of Fulcrum Therapeutics, Inc. (Nasdaq: FULC) surged over 30% in pre-market trading following the announcement that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Investigational New Drug (IND) application for FTX-6058, a potential treatment for sickle-cell disease (SCD).
$FULC was trading at $5.81 in pre-market, reflecting a gain of $1.89 (+48.21%).
Shifting focus, Macy’s, Inc. (NYSE: M) reported second quarter 2023 earnings at $0.26 per share, surpassing the consensus EPS estimate of $0.13. The company's quarterly sales amounted to $5.28 billion, slightly exceeding analysts' projected revenue of $5.09 billion.
In pre-market, $M was trading at $14.43, down $0.30 (-2.04%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Watch: What to Expect from Walt Disney, AppLovin, and DoorDash
August 03rd, 2025Key Earnings on Deck: AMD, Caterpillar, and Amgen to Post Q2 Results
August 03rd, 2025Palantir, Freshpet, and ONEOK Set to Unveil Q2 Earnings
August 03rd, 2025Herbal Works Inc. Announces Three Signature Scents of CBD Bath Bombs
August 01st, 2025
Member Login